Opioid-sparing Effects of Cannabinoids
September 25, 2025
At the September CMCR Investigators’ Meeting, Michael A. Taffe, Ph.D. Professor of Psychiatry at UC San Diego, presented preclinical findings on how cannabinoids interact with opioids using an e-cigarette vapor inhalation platform. His work addressed a central question: does cannabis reduce or enhance opioid liability?
Dr. Taffe showed that vaporized THC reduced oxycodone intake under fixed-ratio schedules, consistent with additive analgesic effects when combined with opioids. However, in progressive-ratio tests—where animals must work harder for each infusion—low-dose THC increased responding for heroin or oxycodone, suggesting enhanced reinforcing value rather than general behavioral suppression. Notably, THC did not alleviate dysphoria during extended access sessions measured with intracranial self-stimulation; despite consuming less opioid, animals still exhibited the same negative affective states.
CBD produced a different pattern. Acute CBD vapor decreased oxycodone intake under easy-access conditions but did not increase progressive-ratio breakpoints, raising the possibility of a therapeutic profile distinct from THC. History and sex also influenced outcomes: animals with chronic THC exposure required higher doses for intake reduction, and male and female rats showed divergent tolerance dynamics.
Dr. Taffe further highlighted long-term consequences of adolescent THC exposure. Repeated exposure during adolescence produced lasting CB1 receptor tolerance and, in adulthood, heightened responding for low-dose fentanyl in females, suggesting persistent alterations in opioid reinforcement. Additional behavioral probes revealed subtle, enduring phenotypes in feeding behavior.
Together, these findings underscore the complexity of cannabinoid–opioid interactions. THC may both reduce opioid consumption and simultaneously enhance opioid reward, while CBD may dampen intake without this reinforcing effect. Dr. Taffe emphasized the translational importance for pain treatment and addiction liability, noting that relapse models remain a critical next step.
Michael A. Taffe, Ph.D.
Dr. Taffe is a Professor in the Department of Psychiatry at UC San Diego since 2019. The work of his lab focuses on the behavioral effects of drugs of abuse using preclinical models to elucidate potential health risks. Some of his recent work on cannabinoids focuses on the lasting consequences of repeated THC exposure in adolescence via e-cigarette vapor inhalation. Additional work examines the interactive effects of THC and cannabidiol when co-administered with opioids such as heroin and oxycodone, including studies on whether THC or CBD reduce the rewarding effects of opioids in self-administration models.